We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma.
- Authors
MacNeill, Amy L.; Weishaar, Kristen M.; Séguin, Bernard; Powers, Barbara E.
- Abstract
Many oncolytic viruses that are efficacious in murine cancer models are ineffective in humans. The outcomes of oncolytic virus treatment in dogs with spontaneous tumors may better predict human cancer response and improve treatment options for dogs with cancer. The objectives of this study were to evaluate the safety of treatment with myxoma virus lacking the <italic>serp2</italic> gene (MYXVΔserp2) and determine its immunogenicity in dogs. To achieve these objectives, dogs with spontaneous soft tissue sarcomas were treated with MYXVΔserp2 intratumorally (<italic>n</italic> = 5) or post-operatively (<italic>n</italic> = 5). In dogs treated intratumorally, clinical scores were recorded and tumor biopsies and swabs (from the mouth and virus injection site) were analyzed for viral DNA at multiple time-points. In all dogs, blood, urine, and feces were frequently collected to evaluate organ function, virus distribution, and immune response. No detrimental effects of MYXVΔserp2 treatment were observed in any canine cancer patients. No clinically significant changes in complete blood profiles, serum chemistry analyses, or urinalyses were measured. Viral DNA was isolated from one tumor swab, but viral dissemination was not observed. Anti-MYXV antibodies were occasionally detected. These findings provide needed safety information to advance clinical trials using MYXVΔserp2 to treat patients with cancer.
- Subjects
SOFT tissue tumors; MYXOMA virus; TUMORS in animals; VIRUS diseases; DNA
- Publication
Viruses (1999-4915), 2018, Vol 10, Issue 8, p398
- ISSN
1999-4915
- Publication type
Article
- DOI
10.3390/v10080398